Deals Shaping The Medical Industry, June 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2016.
You may also be interested in...
The number of PMA and 510(k) applications have been steadily growing and becoming harder to review as they’ve become more complex – which an FDA official says means the agency needs more financial resources.
CEO Vas Narasimhan committed to delivering compound annual growth of 4% from 2020-2026, driven by newer brands plus some pipeline assets.
Deal Snapshot: Seeking to bring a disease-modifying Parkinson’s drug to market, Novartis will team with UCB on developing and commercializing UCB0599, a Phase II oral alpha-synuclein inhibitor.